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Abstract
Background: Over 90% of antibiotics for human use in Europe are prescribed in primary care. We assessed the
congruence between primary care treatment guidelines for skin infections and commensal Staphylococcus aureus
(S. aureus) antimicrobial resistance levels in community-dwelling persons.
Methods: The prevalence of antimicrobial resistance in S. aureus was analysed by taking nose swabs from healthy primary
care patients in nine European countries (total N = 32,032). Primary care treatment guidelines for bacterial skin infections
were interpreted with respect to these antimicrobial resistance patterns. First- and second-choice recommendations were
assessed and considered congruent if resistance to the antibiotic did not exceed 20%.
Results: We included primary care treatment guidelines for impetigo, cellulitis, folliculitis and furuncle. Treatment
recommendations in all countries were consistent: most of the first-choice recommendations were beta-lactams,
both for children and adults. Antimicrobial resistance levels were low, except for penicillin (on average 73% resistance).
Considerable variation in antimicrobial resistance levels was found between countries, with Sweden displaying
the lowest levels and Spain the highest. In some countries resistance to penicillin and azithromycin was significantly
higher in children (4-17 years) compared with adults.
Conclusions: Most of the first- and second-choice recommendations in the treatment guidelines for skin infections
were congruent with commensal S. aureus antimicrobial resistance patterns in the community, except for two
recommendations for penicillin. Given the variation in antimicrobial resistance levels between countries, age
groups and health care settings, national data regarding antimicrobial resistance in the community should be
taken into account when updating or developing primary care treatment guidelines.
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Background
Antimicrobial resistance (AMR) has become an important
public health threat across the globe during recent de-
cades [1-3]. The development of AMR is considered to be
mainly driven by antibiotic use: exposure to antibiotics
leads to the selection of resistant bacteria in the com-
mensal microbiota [4-6]. An important source of exposure
is found in primary care as over 90% of all antibiotics
for human medical use in Europe are prescribed in pri-
mary care [5,7]. Therefore, several studies have advocated
cautious and appropriate prescribing of antibiotics to con-
trol the emergence of AMR [1,8]: empirical treatment with
antibiotics should only take place if necessary and should
ideally include appropriate agents which are effective
against the most common pathogenic bacteria [8].
An inappropriate antibiotic treatment will have several
effects, in the first place for the patient: the effectiveness
of the treatment will be limited. Secondly, unnecessary
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costs will occur for the health care system; and finally,
the exposure to antibiotics could lead to a further increase
of AMR [1,9,10]. Several studies recommend the use of
relevant AMR data when developing or revising primary
care treatment guidelines for bacterial infections [6,8,11].
However, since previous AMR studies have mainly obtained
data from hospitalized populations with higher resistance
levels [6], primary care treatment guidelines might benefit
by integrating AMR patterns from the community [12,13].
S. aureus is a part of the commensal microbiota mainly
manifesting as bacterial skin and soft tissue infections
[14,15]. The incidence of these infections in primary care
is relatively high, especially in children, hereby forming
a considerable cause for antibiotic prescriptions [14,16,17].
Traditionally, methicillin-resistant S. aureus (MRSA) was
confined to hospitals and long-term-care facilities, but
in the last decade MRSA infections have also appeared
in healthy community-dwelling individuals [18-21]. Sev-
eral studies have established the importance of commensal
microbiota as a natural reservoir of bacterial resist-
ance, from which resistance can be acquired by pathogens
[22,23]. By focusing on S. aureus, our study assessed the
congruency of primary care treatment guidelines for
skin infections with AMR data from the community, to
optimize treatment effectiveness.
Methods
Study design
This study was part of the EC-funded APRES study,
aimed at establishing the appropriateness of prescribing
antibiotics in primary care in Europe, by collecting data
on AMR in the community, antibiotic prescription be-
haviour and treatment guidelines in primary care. Nine
countries across Europe participated in APRES, with vary-
ing patterns of antibiotic prescription rates [5]: Austria,
Belgium, Croatia, France, Hungary, the Netherlands, Spain,
Sweden, and the United Kingdom. A detailed overview
of the APRES study design and an analysis of the AMR
results have been published elsewhere [4,24]. This paper
relates the measured AMR patterns in the community to
primary care treatment guidelines for skin infections and
assesses their congruency.
Study participants and AMR
In each of the nine countries, national GP networks se-
lected 20 primary care practices representative of their
total GP population. From each of these practices 200
nasal swabs from patients visiting the practice for non-
infectious reasons were collected [4,24]. Previous studies
[25,26] have shown carriage of S. aureus to be dynamic
and occurring on multiple bodily sites. With the nares
being a common site for S. aureus we assumed our sam-
ple to be representative of all carriage. In order to assess
AMR levels in the commensal flora in the community
(from which resistance can be acquired by pathogens),
we excluded patients with known important risk factors
for AMR: antibiotic use or hospitalisation in the past
3 months. Although S. aureus is not the sole pathogen
causing skin infections, we selected it due to its impact
on public health and relatively high nasal carriage rate
[25,26]. After isolation of S. aureus in 8 national laborator-
ies using standardised procedures, we determined in one
central laboratory whether the isolates were resistant or
susceptible to a range of commonly used antibiotics in
primary care, using cut-off points from the Eucast guide-
lines [4,27].
Treatment guidelines for skin infections
Coordinators of national GP networks in each participat-
ing country supplied the most commonly used and most
recent primary care treatment guidelines for bacterial
skin infections. With the exception of Croatia, all coun-
tries had issued national treatment guidelines for one or
more bacterial skin infections. This resulted in a total of
13 national guidelines from 8 European countries (see
Additional file 1: Table S1), from which we extracted the
prescription recommendations. We focused the analysis
on the antibiotic prescription recommendations for four
common bacterial skin infections in primary care which
are often caused by S. aureus [13]: impetigo, cellulitis, fol-
liculitis and furuncle. We have analysed the treatment
recommendations for antibiotic therapy, distinguishing
between first-choice recommendations and, if available,
second-choice options. Since skin infections are com-
mon in children, we assessed the recommendations for
children separately if this information was available.
Data analysis
To assess the treatment guidelines issued on a national
level, resistance levels for each antibiotic were aggregated
to a national level by dividing the number of resistant S.
aureus isolates per country by the total number of persons
who carried a S. aureus. Separate rates were calculated for
children (4-17 years old) and adults (18+), since treatment
recommendations are often adapted for children. The rec-
ommended antibiotics in the treatment guideline were
linked to the respective AMR levels in that country. Based
on research regarding urinary tract infections, the anti-
biotic treatment recommendations were considered to be
congruent if the resistance to the antibiotic did not exceed
20% [28]. Carriership of S. aureus is linked to a higher risk
of bacterial skin infection [25,29], however, evidence on
the relationship between nasal S. aureus and pathogenic
S. aureus isolated from skin infections is lacking. There-
fore, in our current comparison we assumed that
pathogenic S. aureus related to skin infections shows the
same AMR patterns as nasal colonized S. aureus.
van Bijnen et al. BMC Family Practice 2014, 15:175 Page 2 of 8
http://www.biomedcentral.com/1471-2296/15/175
Not all antibiotics mentioned in the treatment guidelines
were covered on a product level in the resistance testing of
our study. When no AMR data for a specific antibiotic
was available, we used two expert opinions (a medical
microbiologist and pharmacist) to identify a similar anti-
biotic: e.g. since no clarithromycin resistance was tested
we used data of azithromycin resistance (see Additional
file 2: Table S2). Recent studies have shown that resistance
to similar antibiotics can serve as a reliable indicator for
the level of resistance to the original antibiotic [30,31].
Results
Data were obtained from a total number of 32,206 swabs
and in twenty-two percent (N = 6,956) S. aureus was
present. After excluding patients for whom age was un-
known 6037 (87,8%) adults (aged 18+) and 840 (12,2%)
children (aged 4 to 17) were included in our study sample,
of which 56% were female.
Prevalence of resistance
Table 1 (adults) and Table 2 (children) show the AMR
levels of S. aureus for five antibiotics per country. The
difference in resistance was high: on average, S. aureus
showed almost no resistance to oxacillin (0.4%) while re-
sistance to penicillin was high (73%). Resistance to topical
antibiotics was low: averaging 0.4% for mupirocin and
2.8% for fusidic acid. The level of variation between coun-
tries was considerable, especially regarding AMR levels to
azithromycin which ranged from 1.5% in Sweden to 16.9%
in France. Sweden stood out with the lowest AMR levels
to all but one antibiotic. For azithromycin and penicillin
significant differences between adults and children were
found in some countries, with the higher resistance levels
found in children.
Recommendations in treatment guidelines
Some guidelines were not complete in their coverage of
all four infections for both adults and children. Since fol-
liculitis and furuncle are related infections, they were often
discussed together in guidelines and the same recommen-
dations were applied. Overall, the first-choice recommen-
dations for skin infections were very consistent across
Europe. Almost all recommended first-choice antibiotics
were of the B-lactam class, mainly flucloxacillin. Austria
and Sweden also recommended cephalosporins for impe-
tigo, folliculitis and furuncle; while in the Netherlands
macrolides were preferred for cellulitis in children. For
the treatment of impetigo, all guidelines recommended
to first start treatment with a topical antibiotic (most often
fusidic acid). The second-choice recommendations con-
sisted of a wider range of antibiotics. Most countries used
the same antibiotic for adults and children, with an adjusted
dosage for children.
Congruency of first- and second-choice antibiotics with
AMR patterns
One can assess the congruency of the recommendations
with AMR patterns by determining whether the resistance
to the antibiotics is <20% (Tables 3 and 4) [28]. As previ-
ously mentioned low resistance to the topical agents was
found in S. aureus, so the topical treatment recommenda-
tions were all congruent with AMR in the community.
Adults
All first choice recommendations for oral treatment were
congruent with the AMR patterns. In Austria (for cellulitis
and erysipelas) and Spain (for impetigo) a parenteral treat-
ment with penicillin was advised, which was not congruent
with the high penicillin resistance rates found in S. aureus.
The second-choice antibiotic treatment recommenda-
tions were also congruent, with measured resistance levels
Table 1 Resistance rates of S. aureus isolates in nine European countries – adults 18+
Resistance rates (%) (95% confidence interval)
Country Swabs Isolates of
S. aureus
Azithromycin Clindamycin Erythromycin Oxacillin Penicillin Fucidic
acid
Mupirocin
Austria 3168 522 (16.5%) 12.8** (6.3-19.4) 11.1 (4.9 - 17.3) 12.6** (6.1-19.1) 1.5 (0-3.9) 64.4 (55-73.8) 1.0 (0-3.0) 0.2 (0-1.1)
Belgium 2892 552 (19.1%) 16.3 (9.1-23.5) 14.4 (7.5-21.3) 16.3 (9.1-23.5) 2.2 (0-5.1) 72.5 (63.7-81.3) 3.4 (0-7.0) 0.4 (0-1.6)
Croatia 3380 601 (17.8%) 5.8 (1.2-10.4) 5.5 (1-10) 5.8 (1.2-10.4) 2.3 (0-5.2) 75.4** (67-83.8) 0.2 (0-1.1) 0.7 (0-2.3)
France 3536 777 (22.0%) 17.5 (10.1-25.0) 14.9* (7.9-21.9) 17.1 (9.7-24.5) 1.8 (0-4.4) 74.4 (65.8-83) 4.0 (0.2-7.8) 0.1 (0-0.7)
Hungary 2883 359 (12.5%) 10.3** (4.3-16.3) 10.3** (4.3-16.3) 10.3** (4.3-16.3) 1.9 (0-4.6) 71.0** (62.1-79.9) 0.3 (0-1.4) 0.3 (0-1.4)
NL 3491 947 (27.1%) 6.9 (1.9-11.9) 5.2 (0.8-9.6) 5.5 (1.0-10.0) 1.0 (0-3.0) 68.4 (59.3-77.5) 5.2 (0.8-9.6) 0
Spain 3563 620 (17.5%) 11.5 (5.3-17.8) 9.5 (3.8-15.2) 11.0 (4.9-17.1) 1.3 (0-3.5) 86.0* (79.2-92.8) 1.1 (0-3.1) 1.6 (0-4.1)
Sweden 2859 846 (29.6%) 1.3 (0-3.5) 11.8 (5.5-18.1) 13.0 (6.4-19.6) 0 64.3* (54.9-73.7) 1.9 (0-4.6) 0
UK 3152 811 (25.7%) 8.6 (3.1-14.1) 7.5 (2.3-12.7) 8.9 (3.3-14.5) 1.6 (0-4.1) 73.4 (64.7-82.1) 7.8 (2.5-13.1) 0
**Significant difference with children under p < 0.05.
*Significant difference with children under p < 0.1.
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Table 3 Congruency of treatment recommendations for skin infections in adults with national commensal S. aureus
resistance rates
Topical AB Resistance rate* First choice systemic AB Resistance rate* Second choice systemic AB Resistance rate*
Impetigo
Austria Fusidic acid 1.0 Cephalosporin No data Amoxicillin + Clavulanic acid 1.5
Belgium Fusidic acid 3.4 Flucloxacillin 2.2 Clarithromycin 16.3
France Fusidic acid 4.0 No specific advice
Hungary No guideline
Netherlands Fusidic acid 5.2 Flucloxacillin 1.0 Azithromycin 6.9
Spain Mupirocin 1.6 Penicillin (IM)/Cloxacillin 86.0 Clindamycin 9.5
1.3
Sweden Retapamulin 0 Flucloxacillin 0 Cefadroxil No data
UK Fusidic acid 7.8 Flucloxacillin 1.6 Clarithromycin 8.9
Cellulitis
Austria Penicillin (parenteral) 64.4 Clindamycin 11.1
Belgium Flucloxacillin 2.2 Clindamycin 14.4
France No guideline
Hungary No guideline
Netherlands Flucloxacillin 1.0 Claritromycin 5.5
Spain Cloxacillin 1.3 Amoxicillin + Clavulanic acid 1.3
Sweden No guideline
UK Flucloxacillin 1.6 Ery/Clarithromycin 8.9
Folliculitis and Furuncle
Austria Cephalosporin No data Amoxicillin + Clavulanic acid 1.5
Belgium No guideline
France No guideline
Hungary No guideline
Netherlands Flucloxacillin 1.0 No second choice
Spain Cloxacillin 1.3 No second choice
Sweden Flucloxacillin 0 Cefadroxil No data
UK Flucloxacillin 1.6 Ery/Clarithromycin 8.9
*A recommendation is congruent if the resistance rate in S. aureus to that antibiotic is <20%. Data in bold indicate a resistance rate of >20%.
Table 2 Resistance rates of S. aureus isolates in nine European countries – children <18
Resistance rates (%) (95% confidence intervals)
Country Swabs Isolates of
S. aureus
Azithromycin Clindamycin Erythromycin Oxacillin Penicillin Fucidic
acid
Mupirocin
Austria 111 23 (20.7%) 30.4** (21.4-39.4) 13.0 (6.4-19.6) 30.4** (21.4-39.4) 0 73.9 (65.3-82.5) 4.3 (0.3-8.3) 0
Belgium 101 30 (22.9%) 16.7 (9.4-24) 16.6 (9.3-23.9) 16.6 (9.3-23.9) 0 63.3 (53.9-72.7) 0 0
Croatia 562 152 (27.0%) 5.3 (0.9-9.7) 4.6 (0.5-8.7) 5.3 (0.9-9.7) 0.7 (0-2.3) 88.2** (81.9-94.5) 0 0
France 309 94 (30.4%) 11.7 (5.4-18.0) 8.5 (3.0-14.0) 10.6 (4.6-16.6) 1.1 (0-3.1) 79.8 (71.9-87.7) 2.1 (0-4.9) 0
Hungary 930 171 (18.4%) 16.4** (9.1-23.7) 16.4 (9.1-23.7) 16.4 (9.1-23.7) 0.6 (0-2.1) 86.0** (79.2-92.8) 0 0
NL 323 119 (36.8%) 5.9 (1.3-10.5) 3.4 (0-7) 4.2 (0.3-8.1) 0 73.1 (64.4-81.8) 0.5 (0-1.9) 0
Spain 427 146 (34.4%) 12.3 (5.9-18.7) 10.3 (4.3-16.3) 12.3 (5.9-18.7) 0.7 (0-2.3) 91.8* (86.4-97.2) 0 3.4 (0 -7.0)
Sweden 345 104 (30.1%) 2.9 (0-6.2) 2.9 (0-6.2) 2.9 (0-6.2) 0 73.1* (64.4-81.8) 2.0 (0-4.7) 0
UK No children in study sample due to ethical considerations
**Significant difference with adults under p < 0.05.
*Significant difference with adults under p < 0.1.
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of <20%, although for Belgium some recommended anti-
biotics exceeded 15% resistance. We found that all recom-
mendations in the Swedish guidelines concerned antibiotics
with an AMR level of 0%.
Children
Only oral therapy was advised for children, in most cases
consisting of the same antibiotic that is used for adults
(flucloxacillin) but with adjusted dosages. All recommended
antibiotics showed a resistance level of <20% and were
therefore congruent.
Discussion
This study assessed the congruency of primary care treat-
ment guidelines for bacterial skin infections with nasal
AMR levels of S. aureus in the community in nine European
countries.
Congruency of recommendations
To assess the congruency of recommendations we used
a threshold of 20%: antibiotics to which S. aureus has re-
sistance rates of <20% are considered congruent [28]. Our
study showed that most of the first- and second-choice
recommendations in the treatment guidelines were con-
gruent with AMR patterns in nasal S. aureus in the com-
munity, except for two recommendations for penicillin.
Azithromycin was appropriate in the Netherlands, but the
relatively high resistance rates in other countries (up to
30%) warrant a cautious use of this antibiotic for skin
infections.
Given the resistance levels to penicillin in nasal S. aureus
in the community, our findings suggest that it should not
be used as a first- or second-choice antibiotic for S. aureus
infections in primary care. Most guidelines for skin in-
fections that we assessed were already congruent with
Table 4 Congruency of treatment recommendations for skin infections in children with national commensal S. aureus
resistance rates
Topical AB Resistance rate* First choice systemic AB Resistance rate* Second choice systemic AB Resistance rate*
Impetigo
Austria Fusidic acid 4.3 Cephalosporin No data Amoxicillin + clavulanic acid 0
Belgium Fusidic acid 0 Flucloxacillin 0 Clarithromycin 16.6
France No guideline
Hungary No guideline
Netherlands Fusidic acid 0.5 Flucloxacillin 0 Azithromycin 5.9
Spain No guideline
Sweden Retapamulin 0 Cefadroxil No data Flucloxacillin 0
UK Fusidic acid No data Flucloxacillin No data Clarithromycin No data
Cellulitis
Austria No guideline
Belgium Flucloxacillin 0 No second choice
France No guideline
Hungary No guideline
Netherlands Clarithromycin 4.2 Azithromycin 5.9
Spain No guideline
Sweden No guideline
UK Flucloxacillin No data Ery/Clarithromycin No data
Folliculitis and Furuncle
Austria Cephalosporin No data Amoxicillin + Clavulanic acid 0
Belgium No guideline
France No guideline
Hungary No guideline
Netherlands No guideline
Spain No guideline
Sweden No guideline
UK Flucloxacillin No data Ery/Clarithromycin No data
*A recommendation is congruent if the resistance rate in S. aureus to that antibiotic is <20%.
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this finding as they did not recommend the use of peni-
cillin, except for two first-choice recommendations for
penicillin in Austria and Spain. The penicillin recommen-
dation for Austria was also used for erysipelas, which is
often caused by a streptococcus. The same was true for
non-bullous impetigo, for which penicillin was recom-
mended in Spain [32]. Literature regarding AMR levels
in streptococci indicates a high susceptibility for peni-
cillin [33], implying these recommendations might be
congruent as well in Austria and Spain.
Strengths and limitations
The strength of our study is the broad scope of the data
from nine countries across Europe (North, South, East
and West), with a high variation in antibiotic use [5]. Our
study is also unique as it assesses the congruency of treat-
ment guidelines for S. aureus skin infections in primary
care based on the prevalence of antibiotic resistance
patterns. The treatment guidelines are issued nationally
and have been supplied by experts who are aware of the
most frequently used guidelines in their countries. Our
study is complete by covering both recommendations for
adults and for children.
A previous paper presented information on the dosage
and duration of the treatment recommendations. Al-
though the relationship between certain dosage-duration
regimes and the development of resistance is not fully
clear, it is noteworthy that the treatment guidelines from
Sweden recommend higher dosages, while at the same
time low AMR was observed [34].
One limitation of our study is that although it tested re-
sistance to a wide range of antibiotics, not all antibiotic
recommendations in the guidelines were covered on a
one-on-one basis and in some cases we had to use the
prevalence of resistance to a similar antibiotic [30,31].
Also, since we excluded patients with current infections
or risk factors for AMR (antibiotic use or hospitalisation
in the past 3 months), the level of AMR might be an
underestimation for the total population in the commu-
nity. However, given that antibiotic resistance can linger
for up to one year [6], we assume our sample to be a good
approximation of primary care patients.
Another limitation is the assumption we made that the
AMR patterns found in nasal S. aureus are similar to those
of pathogenic S. aureus found in SSTIs. To our knowledge,
this relationship has not been conclusively studied, and
future research might be able to fill this knowledge gap.
Our study is also limited in its choice of pathogen: we
focussed on S. aureus due to its relatively high prevalence
and impact on public health but skin infections can also be
caused by a Streptococcus bacteria which may have other
AMR patterns and would be relevant to also consider in
treatment guidelines. However, since the main pathogen
for these skin infections is S. aureus we emphasize its
importance and recommend that resistance patterns of this
pathogen are taken into account when updating or devel-
oping treatment guidelines for skin infections. Finally, al-
though our study uses aggregated data, possible regional
differences in AMR patterns of pathogens could also be
integrated into empiric treatment guidelines.
Implications for primary care
Most AMR studies present data from non-community set-
tings (e.g. the hospital setting) [34] and there is limited data
on antibiotic resistance in the community. The prevalence
of resistance of S. aureus we found in primary care is lower
than the levels reported in hospitals [4,35] and we recom-
mend that recent national AMR data from the community
should be taken into account to create more effective and
evidence-based treatment guidelines for primary care. In
such initiatives other factors affecting evidence-based prac-
tice, such as the implementation process or adherence
to guidelines, should also be incorporated [36]. Evidence-
based guidelines are, however, a first step to control the
development of antibiotic resistance.
Conclusions
Our comparison of primary care treatment guidelines with
AMR patterns of commensal S. aureus in the community
showed that not all European countries have developed
national guidelines for the treatment of common skin
infections in primary care and emphasizes the need to
develop treatment guidelines in these countries. The first-
and second-choice recommendations in the available treat-
ment guidelines proved to be congruent with the national
AMR patterns found in nasal colonized S. aureus: almost
all recommendations concerned antibiotics to which S.
aureus had low resistance levels (<20%). Given the high
resistance to penicillin that has been demonstrated for
commensal S. aureus, we recommend that this anti-
biotic should not be used in primary care treatment of
S. aureus related bacterial skin infections. Based on the
variation in antimicrobial resistance levels between coun-
tries, age groups and health care settings, national data
regarding antimicrobial resistance in the community should
be taken into account when updating or developing
primary care treatment guidelines.
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